Combined pembrolizumab and bevacizumab therapy effectively inhibits non-small-cell lung cancer growth and prevents postoperative recurrence and metastasis in humanized mouse model

Antibodies targeting the programmed cell death protein 1/programmed cell death ligand-1 (PD-1/PD-L1) pathway have dramatically changed the treatment landscape of advanced non-small cell lung cancer (NSCLC). However, combination approaches are required to extend this benefit beyond a subset of patien...

Descripción completa

Detalles Bibliográficos
Autores principales: Qiao, Tianyun, Zhao, Jinbo, Xin, Xiangbing, Xiong, Yanlu, Guo, Wenwen, Meng, Fancheng, Li, Hui, Feng, Yangbo, Xu, Hui, Shi, Changhong, Han, Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2022
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110651/
https://www.ncbi.nlm.nih.gov/pubmed/36357599
http://dx.doi.org/10.1007/s00262-022-03318-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10110651/
https://www.ncbi.nlm.nih.gov/pubmed/36357599
http://dx.doi.org/10.1007/s00262-022-03318-x

Ejemplares similares